These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27396730)

  • 1. Treatment of Multifocal Renal Cell Carcinoma in a Solitary Kidney With Nivolumab.
    Shinder B; Farber NJ; Mayer T; Singer EA
    Clin Genitourin Cancer; 2017 Feb; 15(1):e165-e167. PubMed ID: 27396730
    [No Abstract]   [Full Text] [Related]  

  • 2. Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab.
    Adra N; Cheng L; Pili R
    Clin Genitourin Cancer; 2017 Jun; 15(3):e517-e519. PubMed ID: 28110836
    [No Abstract]   [Full Text] [Related]  

  • 3. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
    Joseph RW; Chatta G; Vaishampayan U
    Urol Oncol; 2017 Apr; 35(4):142-148. PubMed ID: 28259541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
    Buti S; Bersanelli M
    Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome.
    Ruiz-Bañobre J; Abdulkader I; Anido U; León L; López-López R; García-González J
    APMIS; 2017 Mar; 125(3):259-263. PubMed ID: 28233446
    [No Abstract]   [Full Text] [Related]  

  • 6. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
    Ornstein MC; Rini BI
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab-Induced Development of Pulmonary Sarcoidosis in Renal Cell Carcinoma.
    Zhang M; Schembri G
    Clin Nucl Med; 2017 Sep; 42(9):728-729. PubMed ID: 28737580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active and passive immunotherapy: vaccines and antibodies.
    Oosterwijk E; Divgi C; Bander NH
    BJU Int; 2007 May; 99(5 Pt B):1301-4. PubMed ID: 17441928
    [No Abstract]   [Full Text] [Related]  

  • 9. [Imaging of Metastastic Renal Cell Carcinoma under Therapy with Immune Checkpoint Inhibitors].
    Notohamiprodjo M; Kopp HG; Bedke J
    Rofo; 2017 Apr; 189(4):287-292. PubMed ID: 28335045
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma.
    Rouvinov K; Osyntsov L; Shaco-Levy R; Baram N; Ariad S; Mermershtain W
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1127-e1130. PubMed ID: 28673798
    [No Abstract]   [Full Text] [Related]  

  • 11. Cabozantinib and nivolumab for renal cell carcinoma.
    Worley L
    Lancet Oncol; 2015 Nov; 16(15):e531. PubMed ID: 26481805
    [No Abstract]   [Full Text] [Related]  

  • 12. Monoclonal antibody therapy of kidney cancer.
    Oosterwijk E; Brouwers A; Boerman OC; Larson SM; Old LJ; Mulders P; Divgi CR
    Cancer Treat Res; 2003; 116():199-212. PubMed ID: 14650834
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
    Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma.
    Takagi T; Yoshida K; Kobayashi H; Kondo T; Iizuka J; Okumi M; Ishida H; Fukuda H; Ishihara H; Tanabe K
    Jpn J Clin Oncol; 2018 Sep; 48(9):860-863. PubMed ID: 30113653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma.
    Teló GH; Carvalhal GF; Cauduro CGS; Webber VS; Barrios CH; Fay AP
    Ann Oncol; 2017 Jan; 28(1):191-192. PubMed ID: 28043983
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination therapy in patients with metastatic renal cell carcinoma.
    Escudier BJ
    Clin Adv Hematol Oncol; 2010 Oct; 8(10):665-6. PubMed ID: 21317861
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)].
    Rexer H
    Urologe A; 2015 Oct; 54(10):1443-5. PubMed ID: 26350358
    [No Abstract]   [Full Text] [Related]  

  • 18. In focus: bevacizumab for renal cell carcinoma.
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features.
    Geynisman DM
    Eur Urol; 2015 Nov; 68(5):912-4. PubMed ID: 26194044
    [No Abstract]   [Full Text] [Related]  

  • 20. Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers.
    Awad MM; Hammerman PS
    J Clin Oncol; 2015 Jun; 33(18):1993-4. PubMed ID: 25918290
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.